{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T18:36:37Z","timestamp":1793730997833,"version":"4.6.1"},"reference-count":77,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,7,25]],"date-time":"2025-07-25T00:00:00Z","timestamp":1753401600000},"content-version":"vor","delay-in-days":205,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Leukemia Research Reports"],"published-print":{"date-parts":[[2025]]},"DOI":"10.1016\/j.lrr.2025.100533","type":"journal-article","created":{"date-parts":[[2025,8,5]],"date-time":"2025-08-05T17:44:38Z","timestamp":1754415878000},"page":"100533","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Mechanisms and signaling pathways of tyrosine kinase inhibitor resistance in chronic myeloid leukemia: A comprehensive review"],"prefix":"10.1016","volume":"24","author":[{"given":"Meriem","family":"Lahmouad","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zahrae","family":"Rachid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rawane","family":"Bellemrrabet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jihane","family":"Zerrouk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khan Wen","family":"Goh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdelhakim","family":"Bouyahya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Youssef","family":"Aboussalah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.lrr.2025.100533_bib0001","series-title":"Molecular Hematology","first-page":"83","article-title":"Chronic myelogenous leukemia","author":"Kantarjian","year":"2024"},{"key":"10.1016\/j.lrr.2025.100533_bib0002","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1002\/ajh.25792","article-title":"Chronic myeloid leukemia: 2020 update on diagnosis, therapy and monitoring","volume":"95","author":"Jabbour","year":"2020","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.lrr.2025.100533_bib0003","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1007\/s11010-022-04576-0","article-title":"Developing therapeutic approaches for chronic myeloid leukemia: a review","volume":"478","author":"Kumar","year":"2023","journal-title":"Mol. Cell. Biochem."},{"key":"10.1016\/j.lrr.2025.100533_bib0004","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1038\/s41408-023-00823-9","article-title":"Management of chronic myeloid leukemia in 2023\u2013common ground and common sense","volume":"13","author":"Senapati","year":"2023","journal-title":"Blood Cancer J."},{"key":"10.1016\/j.lrr.2025.100533_bib0005","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2024.42.16_suppl.e18520","article-title":"Quantifying the financial impact of treatment intolerance in chronic myeloid leukemia on oncology clinical practices: a mixed methods study","volume":"42","author":"Shafrin","year":"2024","journal-title":"JCO"},{"key":"10.1016\/j.lrr.2025.100533_bib0006","doi-asserted-by":"crossref","first-page":"7918","DOI":"10.1182\/blood-2024-210443","article-title":"Global trends of burden of chronic myeloid leukemia based on socio-demographic index (SDI): a comparative epidemiological study","volume":"144","author":"Chaulagain","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.lrr.2025.100533_bib0007","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1002\/ajh.26642","article-title":"Chronic myeloid leukemia: 2022 update on diagnosis, therapy, and monitoring","volume":"97","author":"Jabbour","year":"2022","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.lrr.2025.100533_bib0008","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1038\/s41375-022-01736-5","article-title":"Pathogenesis and management of accelerated and blast phases of chronic myeloid leukemia","volume":"37","author":"Senapati","year":"2023","journal-title":"Leukemia"},{"key":"10.1016\/j.lrr.2025.100533_bib0009","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.lrr.2025.100533_bib0010","article-title":"Current issues in chronic myeloid leukemia: monitoring, resistance, and functional cure","volume":"10","author":"Cortes","year":"2012","journal-title":"J. Natl. Compr. Cancer Netw."},{"key":"10.1016\/j.lrr.2025.100533_bib0011","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/j.clinthera.2012.01.009","article-title":"Dasatinib: from treatment of imatinib-resistant or-intolerant patients with chronic myeloid leukemia to treatment of patients with newly diagnosed chronic phase chronic myeloid leukemia","volume":"34","author":"Abbott","year":"2012","journal-title":"Clin. Ther."},{"key":"10.1016\/j.lrr.2025.100533_bib0012","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1038\/leu.2012.181","article-title":"Nilotinib in imatinib-resistant or imatinib-intolerant patients with chronic myeloid leukemia in chronic phase: 48-month follow-up results of a phase II study","volume":"27","author":"Giles","year":"2013","journal-title":"Leukemia"},{"key":"10.1016\/j.lrr.2025.100533_bib0013","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.1038\/s41375-022-01589-y","article-title":"Bosutinib versus imatinib for newly diagnosed chronic phase chronic myeloid leukemia: final results from the BFORE trial","volume":"36","author":"Br\u00fcmmendorf","year":"2022","journal-title":"Leukemia"},{"key":"10.1016\/j.lrr.2025.100533_bib0015","first-page":"2031","article-title":"A phase 3, open-label, randomized study of asciminib, a STAMP inhibitor, vs bosutinib in CML after 2 or more prior TKIs, blood","volume":"138","author":"Rea","year":"2021","journal-title":"J. Am. Soc. Hematol."},{"key":"10.1016\/j.lrr.2025.100533_bib0016","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1038\/s41375-024-02187-w","article-title":"Long-term outcomes after upfront second-generation tyrosine kinase inhibitors for chronic myeloid leukemia: managing intolerance and resistance","volume":"38","author":"Claudiani","year":"2024","journal-title":"Leukemia"},{"key":"10.1016\/j.lrr.2025.100533_bib0017","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1038\/s41375-021-01387-y","article-title":"Is the Sokal or EUTOS long-term survival (ELTS) score a better predictor of responses and outcomes in persons with chronic myeloid leukemia receiving tyrosine-kinase inhibitors?","volume":"36","author":"Zhang","year":"2022","journal-title":"Leukemia"},{"key":"10.1016\/j.lrr.2025.100533_bib0018","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1080\/17474086.2022.2077187","article-title":"An evaluation of ponatinib as a therapy in adult patients with resistant\/intolerant chronic-phase chronic myeloid leukemia","volume":"15","author":"Yang","year":"2022","journal-title":"Expert Rev. Hematol."},{"key":"10.1016\/j.lrr.2025.100533_bib0019","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1182\/blood.V122.21.650.650","volume":"122","author":"Cortes","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.lrr.2025.100533_bib0020","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1182\/blood.V116.21.207.207","article-title":"ENESTnd update: continued superiority of nilotinib versus imatinib in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP)","volume":"116","author":"Hughes","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.lrr.2025.100533_bib0021","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1182\/blood.V116.21.206.206","article-title":"Dasatinib versus imatinib in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) in the DASISION trial: 18-month follow-up","volume":"116","author":"Shah","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.lrr.2025.100533_bib0022","doi-asserted-by":"crossref","first-page":"4820","DOI":"10.3390\/cancers13194820","article-title":"Resistance to tyrosine kinase inhibitors in chronic myeloid leukemia\u2014from molecular mechanisms to clinical relevance","volume":"13","author":"Alves","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.lrr.2025.100533_bib0023","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1002\/ajh.26550","article-title":"Treatment-free remission in patients with chronic myeloid leukemia following the discontinuation of tyrosine kinase inhibitors","volume":"97","author":"Haddad","year":"2022","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.lrr.2025.100533_bib0024","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1056\/NEJMoa1306494","article-title":"A phase 2 trial of Ponatinib in Philadelphia chromosome\u2013positive leukemias","volume":"369","author":"Cortes","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.lrr.2025.100533_bib0025","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1056\/NEJMoa0912614","article-title":"Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia","volume":"362","author":"Saglio","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.lrr.2025.100533_bib0026","doi-asserted-by":"crossref","first-page":"2260","DOI":"10.1056\/NEJMoa1002315","article-title":"Dasatinib versus Imatinib in newly diagnosed chronic-phase chronic myeloid leukemia","volume":"362","author":"Kantarjian","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.lrr.2025.100533_bib0027","doi-asserted-by":"crossref","first-page":"S430","DOI":"10.1016\/S2152-2650(24)01430-7","article-title":"MPN-384 A phase 2 study of Pemigatinib (FIGHT-203; INCB054828) in patients with myeloid\/lymphoid neoplasms with fibroblast growth factor receptor 1 (FGFR1) gene rearrangement","volume":"24","author":"Vannucchi","year":"2024","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"10.1016\/j.lrr.2025.100533_bib0028","doi-asserted-by":"crossref","first-page":"e190","DOI":"10.1016\/S2352-3026(22)00034-5","article-title":"Venetoclax consolidation after fixed-duration venetoclax plus obinutuzumab for previously untreated chronic lymphocytic leukaemia (HOVON 139\/GiVe): primary endpoint analysis of a multicentre, open-label, randomised, parallel-group, phase 2 trial","volume":"9","author":"Kersting","year":"2022","journal-title":"Lancet Haematol."},{"key":"10.1016\/j.lrr.2025.100533_bib0029","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1038\/s41375-020-0842-9","article-title":"Expert opinion\u2014management of chronic myeloid leukemia after resistance to second-generation tyrosine kinase inhibitors","volume":"34","author":"Hochhaus","year":"2020","journal-title":"Leukemia"},{"key":"10.1016\/j.lrr.2025.100533_bib0030","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1080\/17474086.2024.2440776","article-title":"Understanding and overcoming resistance to tyrosine kinase inhibitors (TKIs) in Chronic myeloid leukemia (CML)","volume":"18","author":"Lagan\u00e0","year":"2025","journal-title":"Expert Rev. Hematol."},{"key":"10.1016\/j.lrr.2025.100533_bib0031","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1080\/07391102.2019.1567390","article-title":"How does the novel T315L mutation of breakpoint cluster region-abelson (BCR-ABL) kinase confer resistance to ponatinib: a comparative molecular dynamics simulation study","volume":"38","author":"Zhang","year":"2020","journal-title":"J. Biomol. Struct. Dyn."},{"key":"10.1016\/j.lrr.2025.100533_bib0032","doi-asserted-by":"crossref","first-page":"4747","DOI":"10.1080\/07391102.2018.1559765","article-title":"Predictive models for designing potent tyrosine kinase inhibitors in chronic myeloid leukemia for understanding its molecular mechanism of resistance by molecular docking and dynamics simulations","volume":"37","author":"Melge","year":"2019","journal-title":"J. Biomol. Struct. Dyn."},{"key":"10.1016\/j.lrr.2025.100533_bib0033","first-page":"37","article-title":"Analysis of mutation characteristics in TKI-resistant chronic myeloid leukemia patients based on next-generation sequencing technology","author":"Huang","year":"2024","journal-title":"J. Leuk. Lymphoma"},{"key":"10.1016\/j.lrr.2025.100533_bib0034","doi-asserted-by":"crossref","first-page":"2","DOI":"10.3390\/scipharm92010002","article-title":"Polymorphisms in drug transporter and metabolism genes associated with resistance to Imatinib in chronic myeloid leukemia: a systematic review and meta-analysis","volume":"92","author":"G\u00f3mez","year":"2023","journal-title":"Sci. Pharm."},{"key":"10.1016\/j.lrr.2025.100533_bib0035","doi-asserted-by":"crossref","first-page":"2311","DOI":"10.3390\/cancers13102311","article-title":"Current views on the interplay between tyrosine kinases and phosphatases in chronic myeloid leukemia","volume":"13","author":"Boni","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.lrr.2025.100533_bib0036","doi-asserted-by":"crossref","first-page":"2827","DOI":"10.1038\/s41375-020-01037-9","article-title":"Declaration of Bcr-Abl1 independence","volume":"34","author":"Zhao","year":"2020","journal-title":"Leukemia"},{"key":"10.1016\/j.lrr.2025.100533_bib0037","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2024.1422565","article-title":"Molecular biomarkers of leukemia: convergence-based drug resistance mechanisms in chronic myeloid leukemia and myeloproliferative neoplasms","volume":"15","author":"Kaehler","year":"2024","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.lrr.2025.100533_bib0038","first-page":"1","article-title":"Asciminib monotherapy in patients with chronic-phase chronic myeloid leukemia with the T315I mutation after\u2265 1 prior tyrosine kinase inhibitor: 2-year follow-up results","author":"Cortes","year":"2024","journal-title":"Leukemia"},{"key":"10.1016\/j.lrr.2025.100533_bib0039","doi-asserted-by":"crossref","first-page":"4161","DOI":"10.2217\/fon-2022-0923","article-title":"Asciminib monotherapy for newly diagnosed chronic myeloid leukemia in chronic phase: the ASC4FIRST phase III trial","volume":"18","author":"Cortes","year":"2022","journal-title":"Future Oncol."},{"key":"10.1016\/j.lrr.2025.100533_bib0040","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1038\/s41375-024-02159-0","article-title":"Dose modification dynamics of ponatinib in patients with chronic-phase chronic myeloid leukemia (CP-CML) from the PACE and OPTIC trials","volume":"38","author":"Jabbour","year":"2024","journal-title":"Leukemia"},{"key":"10.1016\/j.lrr.2025.100533_bib0041","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1056\/NEJMoa2400858","article-title":"Asciminib in newly diagnosed chronic myeloid leukemia","volume":"391","author":"Hochhaus","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.lrr.2025.100533_bib0043","doi-asserted-by":"crossref","first-page":"6987","DOI":"10.1158\/1078-0432.CCR-05-0622","article-title":"Combined Abl inhibitor therapy for minimizing drug resistance in chronic myeloid leukemia: SRC\/Abl inhibitors are compatible with imatinib","volume":"11","author":"O\u2019Hare","year":"2005","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.lrr.2025.100533_bib0044","first-page":"6042","article-title":"PI3-kinase inhibition as a strategy to suppress the leukemic stem cell niche in ph+ chronic myeloid leukemia","volume":"11","author":"Filik","year":"2021","journal-title":"Am. J. Cancer Res."},{"key":"10.1016\/j.lrr.2025.100533_bib0045","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1002\/ajh.24275","article-title":"Chronic myeloid leukemia: 2016 update on diagnosis, therapy, and monitoring","volume":"91","author":"Jabbour","year":"2016","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.lrr.2025.100533_bib0046","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1007\/s10120-020-01069-1","article-title":"Spectrum of activity of dasatinib against mutant KIT kinases associated with drug-sensitive and drug-resistant gastrointestinal stromal tumors","volume":"23","author":"Zeng","year":"2020","journal-title":"Gastric Cancer"},{"key":"10.1016\/j.lrr.2025.100533_bib0047","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1186\/s12885-024-12614-x","article-title":"Ubiquitin-specific proteases (USPs) in leukemia: a systematic review","volume":"24","author":"Zangooie","year":"2024","journal-title":"BMC Cancer"},{"key":"10.1016\/j.lrr.2025.100533_bib0048","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1186\/s13287-021-02659-1","article-title":"Chronic myeloid leukemia stem cells: targeting therapeutic implications","volume":"12","author":"Mojtahedi","year":"2021","journal-title":"Stem Cell Res. Ther."},{"key":"10.1016\/j.lrr.2025.100533_bib0049","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1038\/leu.2008.262","article-title":"\u03b2-catenin is essential for survival of leukemic stem cells insensitive to kinase inhibition in mice with BCR-ABL-induced chronic myeloid leukemia","volume":"23","author":"Hu","year":"2009","journal-title":"Leukemia"},{"key":"10.1016\/j.lrr.2025.100533_bib0050","doi-asserted-by":"crossref","first-page":"2065","DOI":"10.1038\/leu.2017.87","article-title":"Combined inhibition of \u03b2-catenin and Bcr\u2013Abl synergistically targets tyrosine kinase inhibitor-resistant blast crisis chronic myeloid leukemia blasts and progenitors in vitro and in vivo","volume":"31","author":"Zhou","year":"2017","journal-title":"Leukemia"},{"key":"10.1016\/j.lrr.2025.100533_bib0051","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1038\/sj.leu.2404657","article-title":"Deregulation and cross talk among Sonic hedgehog, wnt, hox and Notch signaling in chronic myeloid leukemia progression","volume":"21","author":"Sengupta","year":"2007","journal-title":"Leukemia"},{"key":"10.1016\/j.lrr.2025.100533_bib0052","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1038\/s41467-021-27928-8","article-title":"Eliminating chronic myeloid leukemia stem cells by IRAK1\/4 inhibitors","volume":"13","author":"Tanaka","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.lrr.2025.100533_bib0053","article-title":"Impact of genetic variants in the solute carrier (SLC) genes encoding drug uptake transporters on the response to anticancer chemotherapy","volume":"7","author":"Marin","year":"2024","journal-title":"Cancer Drug Resist."},{"key":"10.1016\/j.lrr.2025.100533_bib0054","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1124\/dmd.121.000704","article-title":"Transcriptional regulation of solute carrier drug transporters","volume":"50","author":"Zhou","year":"2022","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.lrr.2025.100533_bib0055","doi-asserted-by":"crossref","DOI":"10.1016\/j.drudis.2023.103537","article-title":"ATP-binding cassette efflux transporters and MDR in cancer","volume":"28","author":"Pote","year":"2023","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.lrr.2025.100533_bib0056","doi-asserted-by":"crossref","first-page":"461","DOI":"10.3390\/antiox13040461","article-title":"Oxidative stress and chronic myeloid leukemia: a balance between ROS-mediated pro-and anti-apoptotic effects of tyrosine kinase inhibitors","volume":"13","author":"Allegra","year":"2024","journal-title":"Antioxidants"},{"key":"10.1016\/j.lrr.2025.100533_bib0057","first-page":"1","article-title":"DNA damage response genes as biomarkers of therapeutic outcomes in acute myeloid leukemia patients","author":"Karami","year":"2024","journal-title":"Leukemia"},{"key":"10.1016\/j.lrr.2025.100533_bib0059","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1038\/s42003-024-06547-1","article-title":"Glutathione determines chronic myeloid leukemia vulnerability to an inhibitor of CMPK and TMPK","volume":"7","author":"Huang","year":"2024","journal-title":"Commun. Biol."},{"key":"10.1016\/j.lrr.2025.100533_bib0060","doi-asserted-by":"crossref","DOI":"10.1016\/j.bneo.2024.100014","article-title":"CD302 predicts achievement of deep molecular response in patients with chronic myeloid leukemia treated with imatinib","volume":"1","author":"Kok","year":"2024","journal-title":"Blood Neoplasia"},{"key":"10.1016\/j.lrr.2025.100533_bib0061","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0216368","article-title":"Examination of CD302 as a potential therapeutic target for acute myeloid leukemia","volume":"14","author":"Lo","year":"2019","journal-title":"Plos One"},{"key":"10.1016\/j.lrr.2025.100533_bib0062","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1038\/nm.2438","article-title":"Imatinib potentiates antitumor T cell responses in gastrointestinal stromal tumor through the inhibition of ido","volume":"17","author":"Balachandran","year":"2011","journal-title":"Nat. Med."},{"key":"10.1016\/j.lrr.2025.100533_bib0063","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1038\/s41419-024-06571-3","article-title":"Deciphering the tumor immune microenvironment of imatinib-resistance in advanced gastrointestinal stromal tumors at single-cell resolution","volume":"15","author":"Liu","year":"2024","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.lrr.2025.100533_bib0064","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1186\/s40164-022-00296-9","article-title":"Myeloid-derived suppressor cells in hematologic malignancies: two sides of the same coin","volume":"11","author":"Yu","year":"2022","journal-title":"Exp. Hematol. Oncol."},{"key":"10.1016\/j.lrr.2025.100533_bib0065","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1038\/s41392-023-01341-7","article-title":"Targeting epigenetic regulators to overcome drug resistance in cancers","volume":"8","author":"Wang","year":"2023","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.lrr.2025.100533_bib0066","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1146\/annurev-immunol-080223-044610","article-title":"TET enzymes in the immune system: from DNA demethylation to immunotherapy, inflammation, and cancer","volume":"42","author":"L\u00f3pez-Moyado","year":"2024","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.lrr.2025.100533_bib0067","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1186\/s12885-022-09481-9","article-title":"Aberrant hydroxymethylation in promoter CpG regions of genes related to the cell cycle and apoptosis characterizes advanced chronic myeloid leukemia disease, poor imatinib respondents and poor survival","volume":"22","author":"Guru","year":"2022","journal-title":"BMC Cancer"},{"key":"10.1016\/j.lrr.2025.100533_bib0068","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.1007\/s13577-023-00919-1","article-title":"HDAC inhibitor chidamide overcomes drug resistance in chronic myeloid leukemia with the T315i mutation through the Akt\u2013autophagy pathway","volume":"36","author":"Yin","year":"2023","journal-title":"Hum. Cell"},{"key":"10.1016\/j.lrr.2025.100533_bib0069","doi-asserted-by":"crossref","first-page":"7156","DOI":"10.3390\/ijms22137156","article-title":"Dysregulation of miRNA in leukemia: exploiting miRNA expression profiles as biomarkers","volume":"22","author":"Anelli","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.lrr.2025.100533_bib0070","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1038\/s41408-022-00667-9","article-title":"Epigenetic modifier gene mutations in chronic myeloid leukemia (CML) at diagnosis are associated with risk of relapse upon treatment discontinuation","volume":"12","author":"Adnan Awad","year":"2022","journal-title":"Blood Cancer J."},{"key":"10.1016\/j.lrr.2025.100533_bib0071","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1182\/blood.2024026312","article-title":"Novel treatment strategies for chronic myeloid leukemia","volume":"145","author":"Cruz-Rodriguez","year":"2025","journal-title":"Blood"},{"key":"10.1016\/j.lrr.2025.100533_bib0072","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.883655","article-title":"Comprehensive evaluation of anti-PD-1, anti-PD-L1, anti-CTLA-4 and their combined immunotherapy in clinical trials: a systematic review and meta-analysis","volume":"13","author":"Xiang","year":"2022","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.lrr.2025.100533_bib0073","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1038\/s41408-024-01020-y","article-title":"Clinical outcomes of patients with lymphoid blastic phase of chronic myeloid leukemia treated with CAR T-cell therapy","volume":"14","author":"Liu","year":"2024","journal-title":"Blood Cancer J."},{"key":"10.1016\/j.lrr.2025.100533_bib0074","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1038\/s41375-024-02278-8","article-title":"Asciminib monotherapy in patients with chronic-phase chronic myeloid leukemia with the T315I mutation after\u2265 1 prior tyrosine kinase inhibitor: 2-year follow-up results","volume":"38","author":"Cortes","year":"2024","journal-title":"Leukemia"},{"key":"10.1016\/j.lrr.2025.100533_bib0075","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.bbrc.2023.09.023","article-title":"HDAC inhibitors: promising agents for leukemia treatment","volume":"680","author":"Deng","year":"2023","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.lrr.2025.100533_bib0076","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1111\/cts.13548","article-title":"DNA methyltransferase inhibitor exposure\u2013response: challenges and opportunities","volume":"16","author":"Kagan","year":"2023","journal-title":"Clin. Transl. Sci."},{"key":"10.1016\/j.lrr.2025.100533_bib0077","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1080\/13543784.2024.2388567","article-title":"Investigational CXCR4 inhibitors in early phase development for the treatment of hematological malignancies","volume":"33","author":"Martino","year":"2024","journal-title":"Expert Opin. Investig. Drugs"},{"key":"10.1016\/j.lrr.2025.100533_bib0078","doi-asserted-by":"crossref","first-page":"2426","DOI":"10.1038\/s41375-023-02062-0","article-title":"Identification of multivariable microRNA and clinical biomarker panels to predict imatinib response in chronic myeloid leukemia at diagnosis","volume":"37","author":"Wu","year":"2023","journal-title":"Leukemia"},{"key":"10.1016\/j.lrr.2025.100533_bib0079","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1038\/s41375-023-01929-6","article-title":"Genetic separation of chronic myeloid leukemia stem cells from normal hematopoietic stem cells at single-cell resolution","volume":"37","author":"Chen","year":"2023","journal-title":"Leukemia"},{"key":"10.1016\/j.lrr.2025.100533_bib0080","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1002\/ajh.26836","article-title":"Chronic myeloid leukemia without major molecular response after 2 years of treatment with tyrosine kinase inhibitor","volume":"98","author":"Bidikian","year":"2023","journal-title":"Am. J. Hematol."}],"container-title":["Leukemia Research Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213048925000354?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213048925000354?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,12,4]],"date-time":"2025-12-04T12:48:04Z","timestamp":1764852484000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2213048925000354"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025]]},"references-count":77,"alternative-id":["S2213048925000354"],"URL":"https:\/\/doi.org\/10.1016\/j.lrr.2025.100533","relation":{},"ISSN":["2213-0489"],"issn-type":[{"value":"2213-0489","type":"print"}],"subject":[],"published":{"date-parts":[[2025]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Mechanisms and signaling pathways of tyrosine kinase inhibitor resistance in chronic myeloid leukemia: A comprehensive review","name":"articletitle","label":"Article Title"},{"value":"Leukemia Research Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lrr.2025.100533","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"100533"}}